<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04500002</url>
  </required_header>
  <id_info>
    <org_study_id>aswu/354/3/19</org_study_id>
    <nct_id>NCT04500002</nct_id>
  </id_info>
  <brief_title>Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol Versus Misoprostol Alone in Missed Abortion</brief_title>
  <official_title>Adjuvant Isonicotinic Acid Hydrazide (INH) Pretreatment With Misoprostol for Induction of Abortion in First-trimester Missed Miscarriage: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aswan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aswan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary endpoint was the success rate of adjuvant isonicotinic acid hydrazide (INH) and&#xD;
      misoprostol versus misoprostol alone for medical termination of first-trimester pregnancy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the American college of obstetricians and gynecologists (2005), medical abortion&#xD;
      is an acceptable alternative for surgical procedures in pregnant women with gestational age&#xD;
      of less than 10 weeks based on the last menstrual period&#xD;
&#xD;
      Oral or vaginal misoprostol causes complete abortion in almost 85% of cases within seven days&#xD;
      before the 12th week&#xD;
&#xD;
      Adjuvant isonicotinic acid hydrazide (INH) administration with misoprostol raises the rate of&#xD;
      complete abortion&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>double blind randomized parallel assign controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double blind randomized parallel assign controlled trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with complete abortion</measure>
    <time_frame>12 hours</time_frame>
    <description>number of patients with complete abortion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>time from induction to abortion</measure>
    <time_frame>12 hours</time_frame>
    <description>time from induction to abortion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of the women will undergo dilatation and curettage after failed medical induction of abortion</measure>
    <time_frame>12 hours</time_frame>
    <description>number of the women will undergo dilatation and curettage after failed medical induction of abortion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>IUCD Complication</condition>
  <arm_group>
    <arm_group_label>INH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 tablets of isonicotinic acid hydrazide 300 mg will be given as single daily doses, 5 mg per day for two days at home and the third dose will be given on admission to hospital on day 3 and will be followed by vaginal misoprostol 800 mcg every three hours up to maximum three doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Misoprostol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Misoprostol Alone 800 mcg every three hours up to maximum three doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isonicotinic Acid Hydrazide</intervention_name>
    <description>total dose 900 mg per day for 3 days then Misoprosrol 800mcg will be given to all patients for induction of abortion</description>
    <arm_group_label>INH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol</intervention_name>
    <description>Misoprosrol 800mcg will be given to all patients for induction of abortion</description>
    <arm_group_label>INH</arm_group_label>
    <arm_group_label>Misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Gestational age less than 70 days gestation (&lt;10 wks)&#xD;
&#xD;
          -  Hemoglobin &gt;10 g/dL.&#xD;
&#xD;
          -  BMI between 18.5 kg/m2 and 30 kg/m2.&#xD;
&#xD;
          -  Missed abortion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Molar pregnancy.&#xD;
&#xD;
          -  Fibroid uterus.&#xD;
&#xD;
          -  Uterine anomalies.&#xD;
&#xD;
          -  Coagulopathy.&#xD;
&#xD;
          -  Medical disorder that contraindicate induction of abortion (e.g. heart failure).&#xD;
&#xD;
          -  Previous attempts for induction of abortion in the current pregnancy.&#xD;
&#xD;
          -  Allergy to misoprostol or letrozole.&#xD;
&#xD;
          -  Scared uterus (previous myomectomy, cesarean section, hysterectomy and ruptured&#xD;
             uterus).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women with gestational age of less than 10 week</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>hany f Sallam, md</last_name>
    <phone>+20102435461</phone>
    <phone_ext>002</phone_ext>
    <email>hany.farouk@aswu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>nahla waer Shady</last_name>
    <phone>+201022336052</phone>
    <phone_ext>002</phone_ext>
    <email>hanygyne@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aswan University Hospital</name>
      <address>
        <city>Aswan</city>
        <zip>81528</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 2, 2020</study_first_submitted>
  <study_first_submitted_qc>August 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aswan University Hospital</investigator_affiliation>
    <investigator_full_name>hany farouk</investigator_full_name>
    <investigator_title>A Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Misoprostol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

